← ALL NEWS

FOREIGNPOLICYJOURNAL.COM · 20 Nov 2026 · DENMARK

Novo Nordisk and AI firm nference launch joint venture framework for obesity, diabetes and heart disease

Novo Nordisk and nference, a Cambridge-based data and AI firm, have announced a new alliance built around a framework for co-creating AI-native health companies. The announcement was dated November 18, 2026, and the partnership targets obesity, diabetes and cardiovascular disease.

The technical core is nference's federated AI platform. It will process data alongside Novo's own clinical trial records, looking for patterns in how these diseases progress over time. Novo has more than 66,500 employees worldwide and has built its reputation over a century of metabolic medicine research. That history gives it an unusually deep archive of clinical trial data for the platform to analyse.

A Novo statement quoted in the piece says the collaboration adds new capabilities to the company's ambition, helping it connect scientific insights with people's everyday health challenges. Venky Soundararajan, founder and co-CEO of nference, called it an honor to partner with Novo, whose century-long scientific heritage he said helped establish modern metabolic medicine.

The text available here is fragmentary. It does not give the financial terms, the timeline, the names of any companies to be created, or details of what other data will be combined with Novo's trial records.

For the Nordic AI scene, the deal shows one of the region's largest life sciences companies turning its long-held clinical data into a basis for new AI-driven ventures. It also shows the company working with an outside AI specialist on chronic metabolic and heart disease, rather than building everything in-house.

Read the original ↗